How is hyposomatotropism (growth hormone deficiency [GHD]) treated?

Updated: Jan 24, 2019
  • Author: Sunil Kumar Sinha, MD; Chief Editor: Robert P Hoffman, MD  more...
  • Print
Answer

Management includes the following:

  • Monitor patients with visits every 3 months.
  • Conduct physical examination: Perform funduscopy to exclude pseudotumor cerebri. Pubertal staging should be performed during each visit because gonadal steroids have a notable effect on skeletal maturation. Monitor patients by measuring their height in centimeters and weight in kilograms.
  • Obtain interim histories. Monitor medical therapy. Adjust drug dosages by weight, and monitor patients for adverse effects of therapy (see Medication).
  • For patients whose condition does not respond well to weight-based therapy, some clinicians advocate titrating dosages according to insulinlike growth factor (IGF)-1 levels. The goal is to maintain an IGF-1 value in the upper quartile for the child's age and sex.
  • Bone age can be used to determine the remaining growth potential for patients with GHD who are approaching their final height. Bone ages have no proven role in monitoring GH therapy.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!